Impact of pre-existing dengue immunity on human antibody and memory B cell responses to Zika. by Andrade, Paulina et al.
UC Berkeley
UC Berkeley Previously Published Works
Title
Impact of pre-existing dengue immunity on human antibody and memory B cell 
responses to Zika.
Permalink
https://escholarship.org/uc/item/8v3864cm
Journal
Nature Communications, 10(1)
Authors
Andrade, Paulina
Gimblet-Ochieng, Ciara
Modirian, Faraz
et al.
Publication Date
2019-02-26
DOI
10.1038/s41467-019-08845-3
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
ARTICLE
Impact of pre-existing dengue immunity on human
antibody and memory B cell responses to Zika
Paulina Andrade1,2, Ciara Gimblet-Ochieng3, Faraz Modirian1, Matthew Collins3,7, Maritza Cárdenas1,
Leah C. Katzelnick1, Magelda Montoya1, Daniela Michlmayr1, Guillermina Kuan4,5, Angel Balmaseda5,6,
Josefina Coloma1, Aravinda M. de Silva3 & Eva Harris 1
Little is known about enduring memory B cell (MBC) responses to Zika virus (ZIKV) and their
relationship with circulating antibodies. Here we comprehensively assess MBC frequency and
specificity alongside serum binding and neutralizing antibody responses to ZIKV ~2 weeks
and ~8 months postinfection in 31 pediatric subjects with 0, 1 or >1 prior infections with the
related dengue virus (DENV). ZIKV infection elicits a robust type-specific MBC response, and
the majority of late convalescent anti-ZIKV serum neutralizing activity is attributable to
ZIKV-specific antibodies. The number of prior DENV infections does not influence type-
specific or cross-reactive MBC responses, although ZIKV has the highest cross-reactivity
with DENV3. DENV cross-reactive MBCs expanded by ZIKV infection decline in number and
proportion by late convalescence. Finally, ZIKV induces greater cross-reactivity in the MBC
pool than in serum antibodies. Our data suggest immunity to DENV only modestly shapes
breadth and magnitude of enduring ZIKV antibody responses.
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The flaviviruses comprise a genus of arthropod-borneviruses that cause extensive endemic and epidemichuman disease worldwide. Dengue virus (DENV) places an
estimated 3.9 billion people in 128 countries at risk of infection,
and up to ~100 million dengue cases occur annually1. The four
serotypes of DENV (DENV1–4) cause a spectrum of illness
ranging from classic dengue fever to the potentially fatal Dengue
Shock Syndrome2. Starting in 2014, Zika virus (ZIKV) emerged
and spread rapidly to many countries, affecting millions of sus-
ceptible individuals, especially in the Americas3,4. As DENV and
ZIKV share the same ecology and mosquito vectors, the same
populations are at risk of infection by these viruses. A minority of
ZIKV infections are symptomatic, and these present clinically
similarly to other flavivirus infections such as dengue5. However,
ZIKV can also cause more severe disease, including microcephaly
and other congenital birth defects when infection occurs in utero,
as well as Guillain–Barré syndrome in adults6–8.
The flavivirus positive-sense RNA genome encodes for three
structural proteins, capsid (C), premembrane/membrane (prM/
M), and envelope (E)—the main target of B cells and protective
antibodies—and seven nonstructural proteins9. E protein amino
acid sequences differ by as much as 40% between DENV ser-
otypes10, and by 41–46% from ZIKV11. DENV-infected indivi-
duals develop B cells targeting epitopes shared between serotypes
(cross-reactive) and B cells targeting epitopes unique to each
serotype (type-specific)12,13. Upon resolution of infection, acti-
vated B cells give rise to two distinct and enduring populations
of antigen-specific cells: memory B cells (MBCs) and serum
antibody-producing long-lived plasma cells (LLPCs)14. Mouse
studies have demonstrated nonredundant function and distinct
breadth of antigen specificity for MBCs and LLPCs, with greater
cross-reactivity within the MBC pool and greater type-specificity
within the serum antibody population following flavivirus infec-
tion15. However, the relationship of LLPCs and MBCs remains
understudied in humans, particularly in the context of sequential
infection by closely related pathogens such as DENV and ZIKV.
Evaluating the relative contribution of MBCs and LLPCs to
protection and disease has been hindered by a lack of studies
systematically characterizing MBCs side-by-side with serum
antibody responses.
A hallmark of flavivirus infections is the induction of MBC and
serum antibodies that cross-react with other flaviviruses. Pro-
tection from secondary dengue is a balance that depends in part
on the quality and quantity of pre-existing type-specific and
cross-reactive serum antibodies as a first line of defense16 and
possibly on secreted antibodies from rapidly reactivated MBCs
as a second line of defense17. Serum responses, especially neu-
tralizing antibodies, have been correlated with protection in
flavivirus vaccine development as well as in natural infection
studies16,18–20. Specific low-to-intermediate levels of cross-
reactive antibodies induced by primary DENV infections have
been implicated in enhanced viral replication and severe disease
during a secondary infection with a new serotype21,22. People
who have recovered from secondary DENV infections maintain
high levels of serotype cross-reactive MBCs and serum anti-
bodies23 that are correlated with long-lasting, cross-protective
immunity to all four DENV serotypes. Although ZIKV is closely
related to the DENV serocomplex, whether lessons learned from
DENV about antibody cross-reactivity and pathogenesis also
apply to ZIKV is still under investigation. Human antibodies
induced by DENV infections that cross-react with ZIKV have
been shown to be protective or enhancing in different cell culture
and animal models of ZIKV infection11,24–27. However, in human
and nonhuman primate studies published to date, DENV infec-
tion history has not been associated with severity of ZIKV
infection and disease28–31.
A few studies have described either serum antibody responses
or isolated monoclonal antibodies (mAbs) from the MBC pool in
ZIKV-infected individuals with and without prior DENV
immunity25,32–35. Several mAbs have been identified targeting
cross-reactive or type-specific epitopes, but these mAbs were
from single time-point samples from a small number of indivi-
duals without detailed information about DENV infection his-
tory. Regarding serum antibodies, ZIKV cross-reactivity is
present during primary and secondary dengue with modest cross-
neutralization during early convalescence that in some cases is
maintained over time24,26,36,37. Low levels of cross-reactivity
and cross-neutralization to DENV are also present during and
after ZIKV-infection, with higher titers observed in people with
prior DENV immunity36,37. However, the contribution of cross-
reactive antibodies to ZIKV neutralization capacity in ZIKV-
infected individuals from endemic areas has not yet been defined.
Further, the full extent of MBC and serum antibody cross-
reactivity between the DENV serocomplex and ZIKV and the
influence of pre-existing DENV immunity on the enduring MBC
and antibody response to ZIKV infection in individuals in
endemic areas remains poorly understood.
In this work, we analyzed MBC frequency and specificity at the
single-cell level alongside the serum antibody response to ZIKV
infection in a well-characterized cohort of pediatric patients
ongoing for 15 years with known prior DENV infection history
from a dengue-endemic setting to address fundamental questions
about properties of type-specific and cross-reactive serum anti-
bodies and MBCs at a polyclonal level. We show that despite
phylogenetic and antigenic relatedness to DENV, ZIKV infection
generates a strong type-specific response in the MBC repertoire
and neutralizing antibody response in serum that is maintained
into late convalescence. We also find that the number of previous
DENV exposures does not influence the development of type-
specific or cross-reactive responses during ZIKV infection. We
demonstrate that a strong ZIKV and DENV cross-reactive
response in the MBC population at early convalescence declines
in magnitude and proportion by late convalescence, although
greater DENV-ZIKV cross-reactivity is maintained in the MBC
pool than in serum antibodies. Finally, we find that in this
population, ZIKV displays higher cross-reactivity toward DENV3
than to other serotypes at the MBC level.
Results
Differential recognition of ZIKV and DENV by ZIKV+MBCs.
We first interrogated MBCs to discern the proportion and mag-
nitude of type-specific and cross-reactive MBCs in patients
who acquired reverse transcription polymerase chain reaction
(RT-PCR)-confirmed ZIKV infection (ZIKV+) following a his-
tory of no (DENV-naïve/ZIKV), one (DENV-ZIKV), or more
than one (+DENV-ZIKV) prior DENV infection (Table 1). The
previous DENV infection history of the ZIKV+ patients was
known because the subjects were enrolled in a long-term pro-
spective dengue study (see Methods).
We used a modified Multi-Color FluoroSpot assay to
determine the MBC specificity at the single-cell level for all four
DENV serotypes and ZIKV38. In order to measure the MBC
response as it transitions from early to late convalescence, we
detected ZIKV- and/or DENV-specific IgG-producing activated
MBCs from patients at ~14 days and ~8 months postinfection
(Fig. 1a). Total IgG-producing activated MBCs were measured in
parallel, denominated activated antibody-secreting cells (ASC)
(Fig. 1a, right). Peripheral blood mononuclear cells (PBMCs)
from flavivirus-naïve patients were also analyzed by the multi-
color FluoroSpot as negative controls (Supplementary Fig. 1 and
2a). In this study, we defined MBCs as cross-reactive if IgG
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binding was detected in the filter for ZIKV and for at least one
DENV serotype, whereas a type-specific MBC clone produced
IgG that only bound to ZIKV. A representative individual from
each infection group is shown in Fig. 1 and Fig. S3a, and all
responses are shown in Supplementary Fig. 3b (DENV-naïve/
ZIKV, n= 11; DENV-ZIKV, n= 12; +DENV-ZIKV, n= 8). The
Multi-Color FluoroSpot results showed that MBCs were pre-
dominantly ZIKV type-specific in the DENV-naïve/ZIKV subject
6188 at ~14 days and ~8 months postinfection (79% and 61%,
respectively) (Fig. 1b). Subjects 5355 (DENV-ZIKV) and 5376
(+DENV-ZIKV), who had been previously infected with DENV,
displayed ZIKV type-specific responses of 46% and 37%,
respectively, at ~14 days postinfection that increased in propor-
tion over time (69% and 47%, respectively). ZIKV-DENV cross-
reactive MBCs accounted for a higher fraction of antigen-reactive
MBCs from subjects 5355 and 5376 at ~14 days postinfection
(43% and 46%, respectively), but not after ~8 months postinfec-
tion (22% and 32%, respectively) (Fig. 1b). The DENV-reactive
response (i.e., MBC-derived IgG binding to any combination of
one or more DENV serotypes, but not reacting to ZIKV) in
Table 1 Characteristics of ZIKV-infected patients
DENV-naïve 1 prior DENV infectiona >1 prior DENV infectionb
Number, n 11 12 8
Sex, n (%) female 3 (27.3) 6 (50) 3 (37.5)
Age in years, mean (SD) 9 (2.55) 11 (1.8) 10 (3.5)
Day of early convalescent sample collectionc, mean (SD) 15 (6.2) 14 (4.0) 14 (4.4)
Month of late convalescent sample collectiond, mean (SD) 8 (1.5) 8 (1.6) 7 (2)
aDesignated DENV-ZIKV group.
bDesignated+DENV-ZIKV group.
cDays postonset of symptoms.
dMonths postonset of symptoms.
6188 DENV-naïve/ZIKV
14 days post-infection
Total = 100
ZIKV-TS
ZIKV&DENV-CR
79%
(208/262)
21%
(54/262)
5355 DENV-ZIKV
14 days post-infection
Total = 100
ZIKV-TS
ZIKV&DENV-CR
DENV 
46%
(92/200)
11%
(26/200)
43%
(85/200)
6188 DENV-naïve/ZIKV
~8 months post-infection
Total = 100
ZIKV-TS
ZIKV&DENV-CR
61%
(50/82)
39%
(32/82)
5355 DENV-ZIKV
~8 months post-infection
Total = 100
ZIKV-TS
ZIKV&DENV-CR
DENV 
69%
(131/190)
10%
(17/190)
22%
(42/190)
5376 +DENV-ZIKV
14 days post-infection
Total = 100
ZIKV-TS
ZIKV&DENV-CR
DENV37%
(44/119)
17%
(20/119)
46%
(55/119)
5376 +DENV-ZIKV
~8 months post-infection
Total = 100
ZIKV-TS
ZIKV&DENV-CR
DENV
47%
(145/312)
21%
(66/312)
32%
(101/312)
a
b
DENV1 filter DENV2 filter DENV3 filter DENV4 filter ZIKV filter Merged filter Total IgG
Fig. 1 Type-specific and cross-reactive IgG-secreting MBC in ZIKV+ patients. MBC responses in patients with RT-PCR-confirmed ZIKV infection and no
(DENV-naïve/ZIKV), one (DENV-ZIKV), or more than one (+DENV-ZIKV) prior DENV infection(s) were analyzed by the Multi-Color FluoroSpot assay at
~14 days and ~8 months postinfection. a Representative images of activated MBCs from patient 6188 (DENV-naïve/ZIKV) after ~14 days postinfection.
Antigen specificity of MBC responses to ZIKV and the four DENV serotypes are shown as spots represented in each filter. The total ASC of activated MBCs
was analyzed in parallel (Total IgG). b Proportion of antigen-reactive MBCs to ZIKV, ZIKV and DENV, and DENV in representative patients from the
DENV-naïve/ZIKV, DENV-ZIKV, and +DENV-ZIKV groups at ~14 days and ~8 months postinfection. ZIKV-TS, MBCs that react with ZIKV and not with any
DENV serotype; ZIKV&DENV-CR, MBCs that react with ZIKV and at least with one DENV serotype; DENV, MBCs that react with one or more DENV
serotypes but not with ZIKV
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subjects 5355 and 5376 were 11% and 24%, respectively, at
~14 days postinfection and remained stable or decreased slightly
in both patients ~8 months postinfection (9% and 21%,
respectively). Similar results were observed in another set of
representative patients as well (Supplementary Fig. 3a). Anti-
bodies secreted from MBCs in supernatants from activated
PBMCs from representative patients from each group demon-
strated reactivity to antigens from all four DENV serotypes and
ZIKV, displaying higher titers to ZIKV than to DENV at the
binding level and also showing ZIKV neutralizing capacity but
mostly undetectable DENV neutralizing antibodies (Supplemen-
tary Fig. 2). Our results suggest that in both DENV-naive and
DENV-immune individuals, a substantial proportion of the
MBC and MBC-derived antibody responses to ZIKV recognize
type-specific epitopes in early and late convalescence.
ZIKV type-specific MBCs are maintained in ZIKV+ patients.
We next analyzed ZIKV type-specific responses in greater detail.
We found that ZIKV type-specific MBCs were generated early
and were maintained over time in each group of patients
regardless of DENV immunity. The DENV-naïve/ZIKV group
had a significantly greater proportion of type-specific MBCs out
of the flavi-reactive memory pool (78%) compared to the DENV-
ZIKV (32%) and +DENV-ZIKV groups (26%) (p < 0.001 for both
groups, Kruskal–Wallis test and Dunn’s test) ~14 days post-
infection (Fig. 2a). At ~8 months postinfection, the same pattern
was detected; nonetheless, a substantial proportion (~40–50%)
of the MBC response was ZIKV type-specific in both
DENV-immune groups (Fig. 2b) with the percent of ZIKV type-
specific MBCs in the DENV-naïve/ZIKV, DENV-ZIKV, and
+DENV-ZIKV groups as 65%, 37.5% and 47%, respectively
(p < 0.05, Kruskal–Wallis test and Dunn’s test). DENV-naïve
subjects also mounted a significantly higher magnitude ZIKV
type-specific MBC response (out of the total ASC memory pool)
compared to the DENV-immune groups at ~14 days postinfec-
tion (median 3.5%, 1.9%, and 1.3%, p < 0.05, Kruskal–Wallis test
and Dunn’s test, Fig. 2c); however, this difference dissipated after
~8 months postinfection, and ZIKV type-specific responses were
maintained in all groups at a similar level (Fig. 2d). Interestingly,
ZIKV type-specific MBC responses did not decrease significantly
in magnitude between early and late convalescence in any group
(Supplementary Fig. 4).
ZIKV and DENV cross-reactive MBCs decrease over time. We
next asked whether ZIKV infection stimulated cross-reactive
MBCs from previous DENV infections and expanded the size of
the cross-reactive MBC pool. At early convalescence (~14 days
post-ZIKV infection), ZIKV and DENV cross-reactive MBCs
constitute 40–50% of the total flavi-reactive MBCs in people with
one or more previous DENV infection. This proportion was
significantly higher than the 20% of cross-reactive MBCs present
in DENV-naïve/ZIKV (p < 0.001 and p < 0.01, respectively;
Kruskal–Wallis test and Dunn’s test, Fig. 3a). However, over time,
the percentage of cross-reactive MBCs decreased in the DENV-
immune groups and modestly increased in the DENV-naïve
group, resulting in a median proportion of cross-reactive MBCs
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Fig. 2 ZIKV type-specific MBC response is maintained over time in ZIKV+ patients. ZIKV type-specific MBC cell responses in ZIKV-infected patients with
no (DENV-naïve/ZIKV), one (DENV-ZIKV), or more than one (+DENV-ZIKV) prior DENV infection. a, b ZIKV type-specific IgG-secreting MBC response
over total antigen response at ~14 days (a) and ~8 months (b) postinfection. c, d ZIKV type-specific IgG-secreting MBC response over total ASC response
at ~14 days (c) and ~8 months (d) postinfection. The median and interquartile range (IQR) are shown for all graphs. Significance was determined by
Kruskal–Wallis test and Dunn’s test; *p < 0.05, **p < 0.01, ***p < 0.001. DENV-naïve/ZIKV, n= 11; DENV-ZIKV, n= 12; +DENV-ZIKV, n= 7 at ~14 days
postinfection (one PBMC sample was not viable) and n= 8 at ~8 months postinfection
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of 26%, 36%, and 32.5% in the DENV-naïve/ZIKV, DENV-ZIKV,
and +DENV-ZIKV groups, respectively (Fig. 3b).
When the frequency of the cross-reactive response was
analyzed over total IgG-producing activated MBCs (ASC), we
found a similar trend of significantly greater ZIKV and DENV
cross-reactive responses at ~2 weeks postinfection in the DENV-
ZIKV and +DENV-ZIKV groups (3.8% and 2.3%, respectively)
compared to the DENV-naïve/ZIKV group (0.7%; p < 0.05,
Kruskal–Wallis test and Dunn’s test) (Fig. 3c). The significantly
higher magnitude of ZIKV and DENV cross-reactive responses
was not sustained over time, and DENV-naïve, DENV-ZIKV and
+DENV-ZIKV had a median proportion of 0.8%, 1%, and 1.2%,
respectively, at ~8 months postinfection (Fig. 3d). The proportion
of ZIKV and DENV cross-reactivity was significantly reduced
over time in the DENV-ZIKV group (p < 0.05, Kruskal–Wallis
test and Dunn’s test), while the reduction of cross-reactivity in
the +DENV-ZIKV group was not significant (Supplementary
Fig. 5).
Previous DENV exposure number does not influence ZIKV
MBCs. In dengue-endemic areas, individuals can be exposed to
more than one DENV infection, and neutralizing antibody
responses become increasingly cross-reactive with iterative
DENV infections23. Therefore, we investigated whether having
one or more than one previous DENV infection would skew the
MBC response following ZIKV infection to be more cross-
reactive. Our data indicate that the average proportions of ZIKV
type-specific and ZIKV-DENV cross-reactive responses at
~14 days and ~8 months postinfection are similar regardless of
the number of prior DENV infections (Fig. 4a, b). The frequency
of both type-specific and cross-reactive MBCs (among total ASC)
was also similar between the two DENV-immune groups at both
time-points assessed (Fig. 4c, d).
Stronger ZIKV type-specific response in serum than in MBCs.
It remains unclear to what extent the specificities represented in
the MBC pool parallel those of plasma cell-derived circulating
antibodies following ZIKV infection and whether this varies
based on prior DENV infection history. To directly compare the
extent of cross-reactive binding in MBCs and serum antibodies,
we studied both responses in the same individuals and measured
their correlation ~8 months postinfection. For these experiments,
only ZIKV-reactive MBCs were considered, and the proportion
of ZIKV type-specific and cross-reactive MBCs within that
population were determined (Fig. 5a). We found a strong ZIKV
type-specific response in MBCs that remained dominant in
the DENV-naïve/ZIKV group (median 73.2%, 95% CI: 63.6–78.4,
p < 0.0001 compared to ZIKV and DENV cross-reactive respon-
ses, Mann–Whitney test) several months postinfection but that
was compared to ZIKV and DENV cross-reactive responses in
DENV-ZIKV (median 57.3%, 95% CI: 43–63.4) and +DENV-
ZIKV (median 58%, 95% CI: 44.4–71.3) groups (Fig. 5a).
To examine serum antibody responses, DENV-reactive anti-
bodies were depleted, and depletion was confirmed by elimina-
tion of DENV binding as measured by ELISA following depletion
(Supplementary Fig. 6). The ZIKV type-specific binding antibody
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Fig. 3 ZIKV and DENV cross-reactive MBCs decrease over time in ZIKV+ patients. ZIKV and DENV cross-reactive B cell responses in ZIKV-infected
patients with no (DENV-naïve/ZIKV), one (DENV-ZIKV), or more than one (+DENV-ZIKV) prior DENV infection are shown. a, b ZIKV and DENV cross-
reactive IgG-secreting MBC responses over total antigen response at ~14 days (a) and ~8 months (b) postinfection. c, d ZIKV and DENV cross-reactive
IgG-secreting MBC response over total ASC response at ~14 days (c) and ~8 months (d) postinfection. Median and IQR are shown for all graphs.
Significance was determined by Kruskal–Wallis test and Dunn’s test; *p < 0.05, **p < 0.01, ***p < 0.001. DENV-naïve, n= 11; DENV-ZIKV, n= 12; +DENV-
ZIKV, n= 7 at ~14 days postinfection (one PBMC sample was not viable) and n= 8 at ~8 months postinfection
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-08845-3 ARTICLE
NATURE COMMUNICATIONS |          (2019) 10:938 | https://doi.org/10.1038/s41467-019-08845-3 | www.nature.com/naturecommunications 5
response was defined as the post-DENV depletion value divided
by the value in control bovine serum albumin (BSA)-depleted
serum. The difference between the ZIKV type-specific response
and total response is designated the ZIKV and DENV cross-
reactive antibody response (Fig. 5b). In serum, the anti-ZIKV
binding antibody response was found to be highly type-specific
regardless of DENV infection history: DENV-naïve/ZIKV
(median 97.5%, 95% CI: 91.2–100.7, p < 0.0001, Mann–Whitney
test), DENV-ZIKV (median 74.7%, 95% CI: 60.5–82.9, p < 0.0001,
Mann–Whitney test) and +DENV-ZIKV (median 80.7%, 95%
CI: 57.3–86.9, p < 0.001, Mann–Whitney test), where p values
refer to percent of type-specific compared to percent of cross-
reactive antibodies (Fig. 5b). Correlation analysis indicated no
significant correlation between the proportion of ZIKV type-
specific responses of MBCs with serum antibodies in the DENV-
naïve/ZIKV group (r= 0.41; p= 0.2), a trending correlation in
the DENV-ZIKV group (r= 0.5; p= 0.08), and a significant
positive correlation for the +DENV-ZIKV group (r= 0.94;
p < 0.05) (Fig. 5c).
Type-specific antibodies dominate ZIKV neutralization. To
determine the contribution of type-specific versus cross-reactive
antibodies to ZIKV neutralization capacity, serum samples col-
lected ~8 months postinfection were analyzed before and after
depletion of DENV-reactive antibodies to determine DENV and
ZIKV neutralizing antibody titers (Supplementary Fig. 7). In the
vast majority of cases, the neutralizing antibody titer against
ZIKV was similar between DENV-depleted and control-depleted
samples for each group (Fig. 6a–c), indicating that ZIKV type-
specific antibodies account for the majority of neutralizing
activity. We next analyzed the proportion of type-specific versus
cross-reactive antibodies of the total ZIKV neutralizing antibody
response. The ZIKV type-specific neutralizing antibody response
was defined as the post-DENV depletion neutralization titer
divided by the neutralization titer in control-depleted serum. The
difference between the type-specific response and the total
response is the ZIKV and DENV cross-reactive neutralizing
antibody response (Fig. 6d). The type-specific fraction of ZIKV
responses was significantly higher in the DENV-naïve/ZIKV
(median 71%; p < 0.01, Mann–Whitney test), DENV-ZIKV
(median 71%; p < 0.05, Mann–Whitney test) and +DENV-
ZIKV groups (median 82%; p < 0.01, Mann–Whitney test) when
compared to ZIKV and DENV cross-reactivity (Fig. 6d).
ZIKV infection shows highest MBC cross-reactivity to DENV3.
ZIKV and DENV1–4 are phylogenetically related, but it is still
unclear whether cross-reactivity with ZIKV may vary by DENV
serotype. We tested for specific DENV serotype-ZIKV reactivity
in ZIKV-infected patients who were DENV-naïve or had
experienced prior DENV-infection(s). DENV-infected patients
had been previously exposed to DENV1, DENV2, or DENV3 in
similar numbers (n= 8, 9, 11, respectively) (Supplementary
Fig. 8), and we analyzed them together as one group (DENV-
infected). When comparing the median proportion of ZIKV
cross-reactivity toward DENV1 (1.2%), DENV2 (1.2%), DENV3
(5.5%), and DENV4 (0.9%) at ~14 days postinfection in the
DENV-immune/ZIKV group, we found that ZIKV and DENV3
cross-reactivity was significantly higher compared to ZIKV cross-
reactivity with DENV2 and DENV4 (p < 0.05 and p < 0.01,
respectively, one-way ANOVA test) (Fig. 7a). At ~8 months
postinfection, the median proportion of ZIKV cross-reactivity
toward DENV1 (1.3%), DENV2 (0.8%), DENV3 (3.6%), and
DENV4 (0.8%) again indicated that ZIKV and DENV3 cross-
reactivity was significantly higher compared to the ZIKV cross-
reactivity toward the other three serotypes (p < 0.05, p < 0.01, p <
0.01 to DENV1, DENV2, DENV4, respectively, one-way ANOVA
test) (Fig. 7b). Analysis of the DENV-naïve/ZIKV group at
~14 days postinfection showed a median proportion of ZIKV
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Fig. 4 The number of previous DENV exposures does not affect type-specific and cross-reactive MBC responses. Comparison of ZIKV type-specific and
ZIKV and DENV cross-reactive responses in ZIKV-infected patients with one (DENV-ZIKV) or more than one (+DENV-ZIKV) prior DENV exposure at
~14 days and ~8 months postinfection. a Proportion of ZIKV type-specificity (TS) of DENV-ZIKV and+DENV-ZIKV subjects over total antigen response. b
Proportion of ZIKV & DENV cross-reactivity (CR) of DENV-ZIKV and +DENV-ZIKV subjects over total antigen response. c Frequency of type-specific
responses of DENV-ZIKV and+ DENV-ZIKV subjects over total activated MBCs (ASC). d Frequency of cross-reactive responses of DENV-ZIKV and
+DENV-ZIKV subjects over total ASC. The median and IQR are shown for all graphs. Statistical analysis was performed by Mann–Whitney test comparing
DENV-ZIKV and +DENV-ZIKV at each time point, but no significant differences were found among different groups. DENV-naïve, n= 11; DENV-ZIKV, n=
12; +DENV-ZIKV, n= 7 at ~14 days postinfection (one PBMC sample was not viable), and n= 8 at ~8 months postinfection
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cross-reactivity with DENV1, DENV2, DENV3, and DENV4 of
0.5%, 0.6%, 2.2%, and 0.6%, respectively. ZIKV and DENV3
cross-reactivity was significantly higher compared to DENV4
cross-reactivity (p < 0.05, one-way ANOVA test) (Fig. 7c). After
~8 months postinfection, ZIKV cross-reactivity with DENV3
(2.5%) was again significantly higher when compared to DENV1
(1.1%), DENV2 (1.4%), and DENV4 (0.8%) cross-reactivity
(p < 0.05, p < 0.01, p < 0.05, respectively, one-way ANOVA test)
(Fig. 7d). Certain DENV-infected patients who presented strong
cross-reactivity towards ZIKV and DENV3 (e.g., 27% in patient
4006) at the MBC level (Fig. 7e) also displayed a substantial
decrease in ZIKV neutralizing titers when DENV-reactive anti-
bodies were depleted, indicating a higher proportion of neu-
tralizing activity attributable to cross-reactive antibodies (Fig. 7f).
Discussion
To date, most ZIKV B cell studies have focused on panels of
mAbs obtained at a single time-point after ZIKV infection from a
small number of individuals without detailed knowledge of prior
DENV infection history25,32–35. Recent advances have improved
our understanding of the specificity and cross-reactivity of serum
antibody responses to ZIKV and DENV36,37, but the relationship
between serum antibodies and MBC specificity has not been
studied, and a broader analysis of the polyclonal MBC response is
lacking. Here, we performed a comprehensive assessment of MBC
and serum polyclonal responses in 31 ZIKV+ pediatric patients
with one or more well-characterized prior DENV infections as
well as DENV-naïve patients from a cohort of children ongoing
for 15 years. This allowed detailed analysis of the effect of prior
DENV immunity on type-specific and cross-reactive MBC and
serum antibody responses post-ZIKV infection.
The novel Multi-Color FluoroSpot assay allowed us to estimate
the specificity of each MBC to DENV1-4 and ZIKV and the
overall magnitude and proportion of MBCs that were reactive
to DENV only, ZIKV only, or ZIKV and DENV. We found
that ZIKV infection induced a strong type-specific MBC
response in the presence or absence of prior DENV immunity
that was maintained over time. Zika patients with one or more
prior DENV infections exhibited a higher proportion of ZIKV/
DENV cross-reactivity during early convalescence when com-
pared to DENV-naïve patients, suggesting the activation of
DENV immunological memory, consistent with previous
publications26,32,34. However, over time, the magnitude and
proportion of cross-reactive responses decreased in both DENV-
ZIKV and +DENV-ZIKV groups and became similar to ZIKV
type-specific responses. In contrast, the cross-reactivity of MBCs
from DENV-naïve/ZIKV+ subjects increased slightly over time,
similar to observations in primary DENV infections39, probably
due to ongoing dynamics of selection, differentiation, and
maintenance within the recently activated MBC population for
months after infection. Our data suggest that ZIKV infection after
prior DENV exposure engenders distinct MBC responses com-
pared to a secondary DENV infection. Secondary ZIKV infection
leads to a strong and enduring type-specific response, whereas in
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a secondary DENV infection, cross-reactive MBC responses
developed during a primary DENV infection are expanded,
maintained, and dominate over type-specific responses to the
subsequently infecting DENV serotype, both at early and late
convalescence40–42.
Our results suggest that MBC responses are more cross-
reactive than serum antibodies. In both individuals who were
DENV-naïve and DENV-immune, serum antibodies following
ZIKV infection displayed a higher proportion of ZIKV type-
specificity at the binding level than MBCs. Overall, serum
antibody-binding responses to ZIKV were almost entirely driven
by type-specific antibodies. In contrast, in MBC responses
following ZIKV infection, DENV-naïve patients had a relatively
greater ZIKV type-specific component, but still had a higher
proportion of DENV-ZIKV cross-reactivity than was present in
serum antibodies, while patients with prior DENV infection had
similar proportions of type-specific and ZIKV/DENV cross-
reactive MBC responses. These results suggest broader antigen
specificity of ZIKV MBC responses in all patients as compared
to serum antibodies, with greater cross-reactivity in the MBC
pool in those with both DENV and ZIKV infection histories than
those who had been infected with only ZIKV. Greater antigenic
breadth in MBCs than LLPCs has been previously proposed in
studies of West Nile virus infection in mice1515
Analysis of ZIKV type-specific responses in MBCs and serum
overall showed no or a weak correlation in the DENV-naïve/
ZIKV+ and DENV-ZIKV groups, respectively. A lack of corre-
lation has also been observed between antibody levels in serum
and peripheral MBCs in other viral infections and could be
explained by the different roles proposed for MBCs and
LLPCs15,43. A stronger correlation was observed for the +DENV-
ZIKV patients, even though the sample size for this group was
smaller, likely because serum antibodies were more cross-reactive
after more than one DENV infection. The role of MBCs in
protection or pathogenesis of secondary DENV infections is
not yet fully understood. MBCs have been implicated as part
of a strong plasmablast response correlated with severe DENV
infection44, while a recent study showed down-regulation of
plasmablast responses in subjects with asymptomatic DENV45.
However, a diverse repertoire within the MBC pool could also be
more likely to be rapidly activated during secondary infections
with strains or serotypes that differ from the prior infecting
pathogen and potentially play a protective role15,46. More studies
simultaneously analyzing both LLPC- and MBC-derived anti-
bodies are needed to clarify the contribution of MBCs to pro-
tection or pathogenesis of subsequent flaviviral infections.
Our specimens were collected from a long-term prospective
cohort study in a dengue-endemic area where ZIKV was recently
introduced. Before the Zika epidemic, no other flaviviruses were
known to co-circulate with DENV in our study site. We had
previously tested our cohort samples for West Nile Virus infec-
tion by neutralization assay, but did not find any evidence47.
Yellow fever is not endemic in Nicaragua, and the vast majority of
the population does not receive the yellow fever vaccine; no
other flaviviruses have been reported in the country. Therefore,
based on the documented DENV infection history of the children
in the cohort study, we were able to analyze the impact of one or
more prior DENV infections on cross-reactivity of the ZIKV/
DENV MBC response. Interestingly, the number of prior DENV
infections did not affect the magnitude or proportion of ZIKV
DE
NV
1
DE
NV
2
DE
NV
3
DE
NV
4
ZIK
V 
DE
NV
1
DE
NV
2
DE
NV
3
DE
NV
4
ZIK
V 
DE
NV
1
DE
NV
2
DE
NV
3
DE
NV
4
ZIK
V 
N
eu
tra
liz
ing
 
Ab
 
tite
r
N
eu
tra
liz
ing
 
Ab
 
tite
r
BSA-depleted
DENV1-4 depleted
BSA-depleted
DENV1-4 depleted
5376 +DENV-ZIKV
BS
A d
ep
l. c
on
tro
l
DE
NV
1-4
 de
ple
ted
100
101
103
102
104
105
100
101
103
102
104
N
e
ut
ra
liz
ing
 A
b 
tite
r
100
101
103
102
104
100
101
103
102
104
105
100
101
103
102
104
105
100
101
103
102
104
105
ZI
KV
 
nA
b 
tite
r
BS
A d
ep
l. c
on
tro
l
DE
NV
1-4
 de
ple
ted
ZI
KV
 
nA
b 
tite
r
DENV-ZIKV DENV-naÏve/ZIKV 
7252 DENV-naÏve/ZIKV 
DENV-naÏve
DE
NV
-
na
Ïve
/ZI
KV
 
BS
A d
ep
l. c
on
tro
l
DE
NV
1-4
 de
ple
ted
ZI
KV
 
nA
b 
tite
r
100
101
103
102
104
105
ZI
KV
 
nA
b 
tite
r
+DENV-ZIKV
DE
NV
-ZI
KV
 
+D
EN
V-Z
IKV
BSA depl. control
DENV1-4 depleted
BSA-depleted
DENV1-4 depleted
4072 DENV-ZIKV
ZIK
V-T
S
ZIK
V&
DE
NV
-CR
 
ZIK
V-T
S
ZIK
V&
DE
NV
-CR
 
ZIK
V-T
S
ZIK
V&
DE
NV
-CR
 
0
25
50
75
100
%
 Z
IK
V 
se
ru
m
 n
Ab
re
sp
on
se
DENV +DENV
** ***
a
c
b
d
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type-specific or ZIKV/DENV cross-reactive MBC responses
maintained into late convalescence. E protein structural features
of the DENV serocomplex may play a role in restricting the
breadth of antibody neutralization recognition to the DENV
serocomplex. Other differences between the envelopes of dengue
viruses and ZIKV, such as maturation state, flexibility and
stability, could also play a role in exposure and immunogenicity
of broadly conserved epitopes48.
In our study, analysis of ZIKV+ subjects from a dengue-
endemic area who had been previously infected with DENV or
who were DENV-naïve showed that ZIKV neutralization capacity
was not substantially reduced after depletion of DENV-reactive
antibodies, suggesting that type-specific antibodies are respon-
sible for most of the neutralization of ZIKV in serum following
natural infections. This is consistent with our preliminary
observation that depleting DENV-reactive antibodies had no
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Fig. 7 ZIKV infection displays highest cross-reactivity to DENV3. The MBC cross-reactivity between ZIKV and DENV was analyzed for each DENV
serotype individually. The analysis was performed in the DENV-naïve/ZIKV+ and DENV-infected/ZIKV+groups. a, b Proportion of ZIKV cross-reactivity
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cross-reactive responses to ZIKV and DENV in MBCs of activated PBMCs from patient 4006 at ~8 months post-ZIKV infection. f DENV-depleted and
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effect on ZIKV neutralizing activity in plasma of two DENV-
immune returned travelers with ZIKV infection36. These findings
are supported by previous studies of ZIKV/DENV cross-reactive
mAbs showing poor cross-neutralization capacity against ZIKV
and DENV11,25,49. In this regard, ZIKV may behave like other
flaviviruses outside the DENV serocomplex, which are not
effectively neutralized by antibodies induced in people exposed
to one or more DENV infections. In humans, primary DENV
infections stimulate high levels of type-specific neutralizing
antibodies against the homologous serotype and lower levels of
cross-reactive antibodies that do not contribute to type-specific
neutralization50. Secondary DENV infections stimulate high
levels of cross-reactive and cross-neutralizing antibodies against
different serotypes with only small fractions of the overall
response attributable to type-specific antibodies to the first and
second infecting serotypes23. Altogether, our findings suggest that
ZIKV as a secondary flavivirus infection after DENV infection
behaves differently from a secondary DENV infection.
Similarly, antibodies from MBC-derived supernatants dis-
played high ZIKV binding titers and neutralizing titers, regardless
of previous DENV immunity. These results reflect that, as found
for serum antibodies, MBC-derived antibodies also have a strong
neutralizing response against ZIKV. Even though MBC-derived
supernatants contained high binding antibody titers against the
different DENV serotypes, neutralizing antibodies to DENV were
undetectable in most of the patients. This suggests that ZIKV
infection generates MBC antibodies that at the functional level
most strongly contribute to ZIKV neutralization. Overall, our
results showed that MBCs, serum antibodies and MBC-derived
antibodies developed post-ZIKV infection are dominated by a
ZIKV-specific response.
Interestingly, a few of our patients did show a substantial
reduction of ZIKV neutralization capacity after depletion of
DENV-reactive antibodies. Specifically, we found higher cross-
reactivity between ZIKV and DENV3, independent of previous
DENV-immune status. Prior to the ZIKV outbreak in 2016 in the
Nicaraguan PDCS, DENV2 was the dominant circulating ser-
otype from 2014 to 2016, preceded by DENV1 from 2012 to 2013,
and DENV3 from 2009 to 201151. It could be that one or a few
highly immunogenic epitopes are conserved between DENV3
and ZIKV. Our patients represented a spectrum of DENV1,
DENV2, and DENV3 infections prior to ZIKV in roughly equal
numbers, yet DENV3/ZIKV cross-reactivity was the highest
observed, including in DENV-naïve Zika cases. This argues that
this cross-reactivity is not simply being driven by a predisposition
to cross-react with the most recent infecting DENV serotype but
rather perhaps by a conserved immunogenic epitope; however,
this needs to be further investigated. Similarly, another study
showed cross-reactivity between ZIKV and DENV1 from
expanded MBC clones, targeting the EDIII lateral ridge32. This
cross-reactivity was associated with high neutralizing responses to
ZIKV32. Thus, prior DENV immunity in humans may have the
potential to boost ZIKV responses to conserved epitopes, and
ZIKV infection alone may have specific cross-reactive epitopes
with some, but not all, DENV serotypes. Further studies are
needed to elucidate the identity of cross-reactive epitopes shared
by ZIKV and DENV3 or other DENV serotypes.
In addition to the crucial role in durable immunity to ZIKV
played by antibody and MBC responses, several mouse studies
have shown a protective role for T cell responses against ZIKV
infection. CD4+ and CD8+ T cells were found to reduce viral
load and severe disease outcomes during ZIKV infection52–54.
CD4+ T cells were shown to help induce an effective neutralizing
antibody response to control ZIKV replication in interferon
receptor-deficient mice53. Moreover, cross-reactive CD8+ T cells
from prior DENV infection can protect against ZIKV infection
during pregnancy in mice55. Human studies have shown that
prior DENV exposure influences the timing, magnitude, and
quality of the T-cell response during ZIKV infection56; never-
theless, it is still unknown whether cross-reactive T cells have a
protective role during ZIKV infection.
This research has several strengths. We have analyzed B cell
responses to ZIKV in a larger number of individuals than pre-
viously reported, who derive from a long-term pediatric dengue
and Zika cohort in an arbovirus-endemic setting. The cohort
study design allows for the documentation of symptomatic and
inapparent DENV infection history of the participants over many
years. This allowed us to use a set of well-characterized samples
with different prior DENV infection history before the ZIKV
epidemic. Serum and MBC analyses from all the patients were
analyzed in parallel at a polyclonal level, differing from previous
studies that have mainly focused on analysis of mAbs. Further-
more, the neutralization and binding capacity of antibodies
deriving from different subsets of B cells (e.g., MBCs and plasma
cells) were studied for their functional and binding capacities.
Finally, we use a novel Multi-Color FluoroSpot assay to examine
the type-specificity and cross-reactivity of ZIKV infection to the
different DENV serotypes.
Our study has some limitations. Because the cell number was
limited in samples from our pediatric study population, we were
only able to perform limited functional analyses to measure
neutralization of MBC-secreted antibodies. However, we did
perform antibody depletions and neutralization assays of serum
antibodies from the same subjects. Additionally, our study
focused on the investigation of B cell responses following ZIKV
infection in DENV-naïve or DENV-immune individuals. We
were not able to study DENV infections in ZIKV-immune sub-
jects, because no DENV infections following ZIKV infection have
yet been observed in the cohort. Such studies are still needed to
address ZIKV and DENV cross-reactivity in DENV-infected
subjects with prior ZIKV infection.
The role of B cells during ZIKV infection is still not completely
understood, and the circulation of ZIKV in dengue-endemic areas
has elicited interest and concern regarding the effect of cross-
reactive responses on protection or exacerbation of disease in
both ZIKV and DENV infections. Although ZIKV is phylogen-
etically closely related to DENV, our results show that ZIKV
generates a B cell and antibody response that has a strongly type-
specific component even in individuals with prior DENV
immunity. These findings reveal that pre-existing immunity in
subjects who had experienced 1 or >1 prior DENV infections only
modestly shapes the breadth and magnitude of enduring ZIKV-
reactive MBC responses to ZIKV and does not preclude de
novo development of ZIKV-specific antibody responses from
naïve B cells. This suggests that a ZIKV vaccine in DENV-
immune individuals would still engender type-specific neutraliz-
ing antibodies to ZIKV. However, after ZIKV infection, both
those with and without prior DENV infections maintain a sub-
stantial subset of MBCs and antibodies that are DENV-ZIKV
cross-reactive, suggesting possible modulation of the MBC and
serum antibody response to DENV infection. This observation
has important implications for protection against or enhance-
ment of subsequent dengue disease. Overall, our study provides
critical insights into cross-reactive and type-specific MBC and
serum antibody responses to DENV and ZIKV in patients with
different DENV infection histories, with implications for natural
infections and vaccine development in areas where ZIKV and
DENV co-circulate.
Methods
Ethics statement. The Pediatric Dengue Cohort Study (PDCS) was reviewed and
approved by the Institutional Review Boards (IRBs) of the University of California,
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Berkeley, and the Nicaraguan Ministry of Health. Parents or legal guardians of all
subjects provided written informed consent, and subjects 6 years of age and older
provided oral assent. The protocol was amended in July 2015 to include screening
for ZIKV infection in participants meeting the study case definition and again in
February 2016 to expand the case definition (see below). These amendments were
approved by the IRBs reviewing the study.
Study design and population. PBMCs were obtained between July 2016 and
March 2017 from ZIKV-infected patients who were DENV-naïve (n= 11) or who
had previously been exposed to DENV once (n= 12) or more than once (n= 8)
(Table 1) in the community-based prospective Pediatric Dengue Cohort Study
(PDCS) of ~3700 children that has been ongoing since 2004 in Managua, Nicar-
agua57. Blood samples were collected from suspected Zika cases who presented
with rash with one or more of the following: conjunctivitis, arthralgia, myalgia,
and/or peri-articular edema, regardless of fever58. ZIKV infection was confirmed by
real-time RT-PCR performed at the National Virology Laboratory of the Ministry
of Health in Managua using either of two triplex assays that simultaneously detect
ZIKV, CHIKV, and DENV infections: the ZCD assay5,59 or the CDC Trioplex
assay60. Samples from ZIKV-positive patients were collected at early (~14 days
postinfection) and late (~8 months postinfection) convalescence (Table 1). The
definition of convalescence follows the norm for the 15 years of our cohort study
and the convention in the dengue field; namely, early convalescent sample collected
14–21 days postonset of illness61–64 and late convalescent >6 months
postillness5757
Confirmed ZIKV-positive cases were classified as DENV-naïve if they entered
the cohort study with no detectable anti-DENV antibodies, as measured by
the DENV Inhibition ELISA (IE) assay, which has a sensitivity of 98.9% compared
to the Hemagglutination Inhibition assay21,47, and had no documented DENV
infections (symptomatic or inapparent) during their time in the cohort. Confirmed
ZIKV-positive cases were classified as DENV-immune if they entered the cohort
study with no detectable anti-DENV antibodies and had one (DENV-ZIKV) or
more than one (+DENV-ZIKV) documented DENV infections during their
time in the cohort. The previous DENV infection history of patients who tested
positive by ZIKV RT-PCR was initially determined by testing annual longitudinal
samples collected before the introduction of ZIKV to Nicaragua. Subjects who
seroconverted or displayed a ≥fourfold increase in antibody titer when pre-ZIKV
annual samples were tested side-by-side using the DENV Inhibition ELISA
assay21,47 were determined to have had at least one previous DENV infection.
Subsequently, longitudinal samples collected annually from before the first DENV
infection through two years after the last DENV infection before the ZIKV
infection for each individual were analyzed by a flow-based neutralization assay to
confirm the number of DENV infections experienced before the ZIKV
infection65,66.
PBMC isolation. For PBMC preparation41,67, blood samples were collected in
Vacutainer tubes (Becton–Dickenson) with 5 mM EDTA as anticoagulant. Upon
receipt at the Nicaraguan National Virology Laboratory, ~5 ml of blood was
transferred into a Leucosep tube (Greiner Bio-One) containing 3 ml of Ficoll
Histopaque (Sigma) and centrifuged at 500g for 20 min (min) at room temperature.
The PBMC fraction was collected and transferred to a tube containing 9 ml of PBS
with 2% fetal bovine serum (FBS; Denville Scientific) and 1% penicillin/strepto-
mycin (Sigma). Cells were washed and pelleted three times by centrifugation at
500g for 10 min and resuspended in RPMI 1640 complete medium (RPMI 1640,
10% FBS, 1% GlutaMAX™, 1% HEPES and 1% penicillin/streptomycin). Before
the third wash, cells were counted using a hemocytometer (Sismex XS-1000i).
After the third wash, cells were resuspended in cryovials at a concentration of
3 × 106 cells/ml in freezing medium (90% FBS, 10% dimethyl sulfoxide) and were
placed in isopropanol containers (Mr. Frosty, Nalgene) at −80 °C overnight
and transferred to liquid nitrogen for storage41,67.
Virus propagation and purification. Aedes albopictus C6/36 cells, kindly donated
by R. Baric (University of North Carolina at Chapel Hill), were grown to 70%
confluence in a 175 cm2 vented tissue culture flask in MEM medium (Life Tech-
nologies) supplemented with 10% FBS (Corning), 1% GlutaMAX™ (Life Technol-
ogies), 1% HEPES (Life Technologies), and 1% penicillin/streptomycin (Sciencell).
The cells were then infected with unconcentrated ZIKV or DENV1–4 for 5 days.
The infectious supernatant was concentrated using a 100-kDa Amicon filter
tube (Millipore) and then layered on a discontinuous 20/55% OptiPrep® (Sigma-
Aldrich) density gradient and ultracentrifuged at 40,000 RPM at 4 °C for 2 h using
a SW41Ti rotor, without brakes. Finally, the purified virus was collected from
the interface between 20 and 55% density and was stored at −80 °C.
Virus quality control. Viral RNA was extracted from unconcentrated virus using a
QIAmp® Viral Mini Kit (Qiagen), and the concentration was determined using
a NanoDrop® Spectrophotometer. To determine the serotype of the virus, RNA
was used in a SuperScript® One-Step RT-PCR with Platinum® Taq (Invitrogen)
assay with the appropriate primers to amplify ZIKV and the four DENV serotypes.
Protein concentration of purified DENV and ZIKV was determined using a
PierceTM BCA Protein Assay Kit (Thermo Scientific). Purified virus was tested
for serotype-specificity by indirect ELISA.
ELISA. Prior to Qdot conjugation, serotype specificity of the detection mAbs
(anti-DENV1 E95, anti-DENV2 E96, anti-DENV3 5J7, anti-DENV4 E88, and anti-
ZIKV ZKA64) was assessed by indirect ELISA38. Briefly, plates were coated with
a dilution of OptiPrep-purified DENV and ZIKV (10 μg/ml) in coating buffer at
37 °C for 2 h, followed by 5 washes with PBS 0.05% Tween (PBS-T), then plates
were blocked with 5% milk in PBS-T for 2 h at 37 °C. Detection mAbs were
incubated at a 1:100 dilution in blocking buffer at 37 °C for 2 h. After five washes
with PBS-T, the plates were incubated with either anti-human horseradish per-
oxidase (HRP) (Jackson ImmunoResearch) (1:1000) or anti-mouse-HRP (Jackson
ImmunoResearch) (1:500) mAbs at 37 °C for 2 h. Plates were then washed five
times with PBS-T and visualized with 3,3′,5,5′-tetramethylbenzidine; the reaction
was stopped with sulfuric acid after 10 min. To ensure serotype specificity, each
mAb was tested against all the different viruses.
Confirmation of DENV antigen depletion was performed by ELISA by directly
coating ELISA plates with purified DENV antigen (100 ng/well), followed by
blocking with 3% nonfat dairy milk (LabScientific, Inc.) and incubating with
sera for 1 h at 37 °C. IgG-binding antibodies were detected with an alkaline
phosphatase-conjugated goat anti-human secondary antibody (Sigma) and
ρ-nitrophenyl phosphate substrate (Sigma). Absorbance was measured at 405 nm
using an Epoch plate reader (BioTek). For the ZIKV-IgG binding ELISA, plates
were coated with a cross-reactive DENV/ZIKV binding antibody (4G2, 100 ng/
well) and blocked with 3% nonfat milk. The plates were then incubated with ZIKV
antigen (stock grown in C6/36 cells and diluted 1:1 in blocking buffet) for 1 h at
37 °C. IgG-binding antibodies were detected as described above.
Conjugation of mAbs to Qdots. After confirmation of mAb quality and specifi-
city, the different mAbs were conjugated to dibenzocyclooctynol (DIBO)-modified
Qdot® nanocrystals. SiteClickTM technology was used to conjugate Qdots (Life
Technologies) directly to the Fc region of purified mAbs (100–125 µg), according
to the manufacturer’s instructions. We used Qdot®525, Qdot®625, Qdot®700, and
Qdot®800 to conjugate four of the five mAbs with this protocol. To label the fifth
mAb, we used the EZ-Link sulfo NHS LC Biotinylation kit (ThermoFisher Sci-
entific) to conjugate several biotin molecules to amino groups on the mAbs. The
biotinylated mAbs were then detected with Qdot 565-labeled Streptavidin.
Multi-Color FluoroSpot. The Multi-Color FluoroSpot38,68 was performed by
activating 96-well IPFL FluoroSpot plates (Cellular Technology Limited) with 70%
EtOH, washing three times, and coating with 2 μg/well of Fcγ fragment-specific
anti-human IgG (Jackson ImmunoResearch). Following overnight incubation at
4 °C, wells were blocked with RPMI 1640 complete culture medium at 37 °C for 2 h.
Previously, PBMCs from ZIKV-infected subjects were thawed in RPMI 1640
complete culture medium with 1 μl/mL DNaseI and activated with IL-2 (1000 U/
mL) and R848 (2.5 μg/μl) for 5 days. Activated PBMCs were counted and plated on
the coated wells in eight 2-fold serial dilutions, following the blocking step. Due to
the potentially low number of antigen-specific cells expected, activated PBMCs
were plated starting with 2.5 × 105–1 × 106 PBMCs in the first well. After 48 h
of incubation at 37 °C, PBMCs were removed via 3 washes with PBS-T, and the
captured Abs were incubated with all five Optiprep®-purified antigens (20 μg/ml in
1× PBS) for 1 h at 37 °C. After three washes with PBS-T, wells were blocked with
human gamma globulin (Jackson ImmunoResearch) diluted 1:500 in 1× DPBS,
followed by incubation with Qdot-labeled mAbs diluted 1:1000 in DPBS 1× for 1 h
at 37 °C. Finally, plates were washed 3 times with PBS-T and once with ddH2O and
dried using a 96-well MultiScreen Vacuum Manifold (Millipore). The MBCs that
reacted with the antigen(s) were visualized as spots representing single cells using a
CTL ImmunoSpot S6 Micro-Analyzer (Cellular Technology Limited). Cross-
reactive pan-DENV and ZIKV antibody EBV-transformed B cells were used as
positive controls. The software was configured by Cellular Technology Limited
(CTL) to count high numbers of spots in one well. The dilution at which ZIKV and
DENV antigen-specific spots were clearly countable was used. For DENV-naïve
ZIKV+ patients, it was necessary to count at a lower dilution of cells in order to
detect sufficient numbers of DENV cross-reactive spots. At lower dilutions, ZIKV
spots were more abundant, but as discussed above, the software was able to count
high numbers of spots accurately.
To determine total IgG-secreting cells, PBMCs were plated in 1:2 serial dilutions
of the stimulated cells starting from 5 × 105 PBMCs/well. Wells were coated with
Fcγ fragment-specific anti-human IgG. Following cell incubation and Ab
deposition, IgG-positive spots were visualized using a polyclonal PE-labeled anti-
human IgG detection mAb (H+ L). Spots were then counted using the CTL reader.
Flow cytometry-based neutralization assay. A flow cytometry-based
neutralization assay using reporter virus particles (RVPs) was performed65,66.
Briefly, in a 96-well round-bottom plate (Corning), a 1:5 dilution of sera and RPMI
1640 complete medium (pH 8.0) was added to all wells in the first row (A).
Subsequently, a threefold serial dilution was performed, from row A down the
plate. The RVP master mix was diluted to generate 7–20% infection and added in a
1:1 volume to all the wells, except the negative control, resulting in a 1:10 dilution
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in Row A. After the incubation period, 40,000 of Raji-DC-SIGN cells in RPMI 1640
complete culture medium were added to each well. After a 48-h incubation at 37 °C
in 5% CO2, the cells were fixed with 2% formaldehyde (16% formaldehyde, Thermo
Scientific) diluted in fluorescence-activated cell sorting (FACS) Buffer (1× DPBS
supplemented with 0.5% BSA [RMBIO®] and 0.02% sodium azide [Sigma
Aldrich]). Following fixation for 30 min in the dark at room temperature, the fixing
solution was decanted and FACS buffer was added to each well for analysis by flow
cytometry.
Depletion of DENV-binding antibodies. A cross-reactive DENV-binding anti-
body (1M7) was conjugated to M280 Tosylactivated Dynabeads (Life Technolo-
gies) at a ratio of 100 μg 1M7 to 5 mg Dynabeads as per the manufacturer’s
instructions. Beads were blocked with 1% BSA/PBS for 1 h at 37 °C. Purified DENV
antigen was harvested from infected Vero cell supernatants then concentrated by
tangential flow ultracentrifugation using the Pellicon mini system with a 100 kD
cutoff membrane (Millipore), flow rate of 400 mL/min, filtration rate of 100 min/
mL, and pressure of 20–30 psi. Using a 15–65% sucrose gradient, the concentrated
virus was purified by ultracentrifugation (SW 40 Ti, Beckman Coulter) at 21,538 rcf
for 18 h at 4 °C. The fractions were run on sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE), and concentrations were then measured by Micro
BCA Protein Assay Kit (Thermo Fisher Scientific). Purified DENV was bound to
the 1M7-Dynabead mixture at a ratio of 100 μg antigen to 5 mg DENV-bound
Dynabeads for 1 h at 37 °C and fixed using 2% paraformaldehyde. Control
beads were incubated with an equal amount of BSA. For depletion, sera were
diluted 1:10 and incubated with 5 μg of DENV-bound Dynabeads in 3 successive
rounds at 37 °C for 1 h each. Following incubation, beads were removed from the
serum using a magnet. Confirmation of DENV antigen depletion was performed
by ELISA (see above).
Focus-reduction neutralization test. Post-depletion neutralization titers were
determined using a focus-reduction neutralization test (FRNT) in which serially
diluted sera were incubated with 50–100 focus forming units of DENV1 (West-Pac
’74), DENV2 (S-16803), DENV3 (CH53489), DENV4 (TVP-376), and ZIKV
(H/PF/2013) in Dulbecco modified Eagle medium with 2% FBS for 1 h at 37 °C.
The serum-virus mixtures were then added to a monolayer of Vero cells in a
96-well plate and incubated for an additional 1 h at 37 °C. After infection, the cells
were washed with 1× PBS and overlaid with Opti-MEM (Gibco) with 2% FBS
and 1% (wt/vol) carboxymethyl cellulose (Sigma). Infected cells were incubated for
2 days at 37 °C and 5% CO2, fixed with paraformaldehyde, permeabilized, blocked
with 3% nonfat dairy milk (LabScientific, Inc.), and stained with cross-reactive
DENV antibodies (4G2 and 2H2). Wells were then incubated with a HRP-
conjugated goat anti-mouse secondary antibody (KPL) and developed with
TrueBlue peroxidase substrate (KPL)
Statistical analysis. FluoroSpot results were analyzed with a Kruskal–Wallis test
and Dunn’s test corrected for multiple comparisons of non-matched and non-
parametric data using Prism 6 software (GraphPad Software). FluoroSpot results
were also analyzed using a two-tailed Wilcoxon test and Mann–Whitney test for
paired comparisons of nonparametric data using Prism 6 software. For depletion
analysis, ELISA binding results were analyzed using a two-way ANOVA test with
Sidak’s multiple comparison test. For neutralization assays, serum concentrations
were log10 transformed and plotted using the sigmoidal dose response (variable
slope) equation, and FRNT50 values were calculated. FRNT50 values from each
sample were compared and analyzed using a two-way ANOVA with Sidak’s
multiple comparison test. Correlation analysis of MBCs and serum reactivity
was performed using a Spearman r test and a nonlinear fit regression analysis
with Prism 6 software.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All main data supporting the findings are available within the article or the Supple-
mentary Information. Other data are available from the authors upon request.
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